Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone
M Lainscak, F Pelliccia, G Rosano, C Vitale… - International journal of …, 2015 - Elsevier
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor
antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which …
antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which …
[HTML][HTML] Mineralocorticoid receptor antagonists therapy in resistant hypertension: time to implement guidelines!
G Maiolino, M Azzolini, GP Rossi - Frontiers in Cardiovascular …, 2015 - frontiersin.org
Despite the availability of anti-hypertensive medications with increasing efficacy up to 50%
of hypertensive patients have blood pressure levels (BP) not at the goals set by international …
of hypertensive patients have blood pressure levels (BP) not at the goals set by international …
重视螺内酯在难治性高血压中的应用
周子华 - 医学新知, 2015 - cqvip.com
重视螺内酯在难治性高血压中的应用-[维普官方网站]-www.cqvip.com-维普网 我的维普 购物车
充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 …
充值 客服 首页 | 期刊大全 | 文献分类 | 优先出版 | 论文检测 | 论文选题 | 在线分享 | 会议平台 …